What is 2q23.1 Microdeletion Syndrome

2q23.1 Microdeletion syndrome is a rare genetic disorder caused by the loss of a small segment of genetic material on the long arm of chromosome 2, specifically affecting the MBD5 gene. This condition typically presents with intellectual disability, speech impairment, seizures, and distinct behavioral patterns often overlapping with autism spectrum disorder.

What causes 2q23.1 Microdeletion syndrome?

The syndrome occurs due to a microdeletion, meaning a tiny piece of DNA is missing from chromosome 2 at position 23.1. The most critical component of this region is the MBD5 gene, which is essential for normal brain development and function. Because this gene is involved in how cells read other genes, its absence in 2q23.1 Microdeletion syndrome disrupts complex neurological pathways, leading to the clinical features observed in patients.

What are the primary symptoms of 2q23.1 Microdeletion syndrome?

While the severity of 2q23.1 Microdeletion syndrome varies significantly between individuals, common clinical manifestations include:

• Significant developmental delay and moderate-to-severe intellectual disability.


• Severe speech impairment, with many individuals remaining non-verbal or having limited vocabulary.


• Behavioral challenges, including sleep disturbances, aggression, or features of autism.


• Seizures, which affect approximately 50% to 75% of diagnosed individuals.


• Distinct facial features and microcephaly (a smaller than average head size).

How common is 2q23.1 Microdeletion syndrome?

2q23.1 Microdeletion syndrome is extremely rare, with fewer than 100 cases documented in international medical literature. Because it is often underdiagnosed, the true prevalence remains unknown. It affects both males and females equally, and there is no known geographic or ethnic predilection. At DiseaseMaps.org, we currently support a small but growing community of 4 individuals living with this condition.

Is 2q23.1 Microdeletion syndrome hereditary?

In the vast majority of cases, 2q23.1 Microdeletion syndrome occurs as a "de novo" (new) mutation. This means the deletion happens randomly during the formation of reproductive cells or early embryonic development, and it is not inherited from the parents. Genetic counseling is strongly recommended for families to assess the extremely low recurrence risk for future pregnancies.

Next steps

• Consult a clinical geneticist for chromosomal microarray testing to confirm the diagnosis.


• Schedule evaluations with pediatric neurologists to manage potential seizure activity.


• Connect with the 2q23.1 Microdeletion syndrome community at DiseaseMaps.org to share experiences with other families.


• Engage early intervention services, including speech, physical, and occupational therapy.

Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD): 2q23.1 microdeletion syndrome.


• Orphanet: MBD5-associated neurodevelopmental disorder.


• OMIM (Online Mendelian Inheritance in Man): #612703.


• PubMed: Clinical and molecular characterization of MBD5-related disorders.